for8krepatent.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): April 19, 2011
 
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
  
000-50513
  
13-3831168
(State or other jurisdiction
  
(Commission
  
(I.R.S. Employer
of incorporation)
  
File Number)
  
Identification No.)
         
   
15 Skyline Drive, Hawthorne, NY
  
10532
   
(Address of principal executive offices)
  
(Zip Code)
         
Registrant’s telephone number, including area code:  (914) 347-4300

Not Applicable
Former name or former address, if changed since last report
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 
 
 

Item 8.01 Other Events
 
On April 19, 2011, Acorda Therapeutics, Inc. issued a press release announcing that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application  No. 11/010,828 entitled “Sustained Release Aminopyridine Composition.”  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.

 
 
 
 
Item 9.01 Financial Statements and Exhibits
 
(d) Exhibits
 
 
Exhibit No.         Description
 
 
99.1             Press Release dated April 19, 2011
 
 
 
 
 
 
 
 
 
 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Acorda Therapeutics, Inc.
     
April 19, 2011
By:
/s/ David Lawrence
   
Name: David Lawrence
   
Title: Chief Financial Officer
 
 




 
 
 

Exhibit Index
 
 
 
Exhibit No.         Description
 
 
99.1             Press Release dated April 19, 2011